Compare HY & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HY | ANL |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 731.6M |
| IPO Year | 2012 | 2022 |
| Metric | HY | ANL |
|---|---|---|
| Price | $37.71 | $10.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 65.6K | ★ 132.6K |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,769,300,000.00 | N/A |
| Revenue This Year | $1.37 | $36.02 |
| Revenue Next Year | $5.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.41 | $0.88 |
| 52 Week High | $44.55 | $17.25 |
| Indicator | HY | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 42.48 |
| Support Level | $34.84 | $6.92 |
| Resistance Level | $37.89 | $12.59 |
| Average True Range (ATR) | 1.52 | 1.15 |
| MACD | 0.20 | -0.09 |
| Stochastic Oscillator | 86.46 | 29.11 |
Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.